[Use of prodigiozan and tactivin for treatment of patients with chronic Klebsiella infections]. / Ispol'zovanie prodigiozana i taktivina v lechenii bol'nykh khronicheskimi klebsiellezami.

Two-stage immunocorrection in patients with chronic Klebsiella infections by consecutive administration of prodigiozan and tactivin, has been shown to facilitate the restoration of the balance of immunoregulating cells, to enhance proliferative response to T- and B-mitogens, thus producing favorable clinical dynamics. The possibility of chronic Klebsiella infections therapy, based on the use of immunocorrecting preparations (prodigiozan and tactivin) and antibiotics capable of intracellular penetration (sumamed and cyprofloxacin) is discussed.

[The current methods for the prevention, diagnosis and surgical treatment of the adhesive complications of peritonitis in children]. / Sovremennye metody profilaktiki, diagnostiki i khirurgicheskogo lecheniia spaechnykh oslozhnenii peritonita u detei.

The paper is based on clinical and experimental findings of one of the postoperative complications of purulent peritonitis, namely adhesion formation. The authors consider that impaired cytodynamic relationship in the focus of peritonitis concurrent with gastrointestinal paresis underlie the pathogenesis of the above-mentioned complication. In this connection, the authors propose a set of anti-adhesive measures, which involves prodigiosane cytomodulation and differential treatment of enteroparesis. Intestinal ultrasonic echocardiography was used for diagnostic purposes. Laparoscopy was employed in the surgical treatment of adhesive complications of peritonitis, which allowed relaparotomy to be eliminated or its traumaticity to be reduced to a great extent. There were no deaths and relapses of adhesive disease.

[Antibiotic therapy of Salmonella infection in infants during the first year of life and methods if its correction]. / Antibiotikoterapiia sal'monelleza u detei pervogo goda zhizni i metody ee korrektsii.

The efficacy of antibiotic therapy of salmonellosis was studied and functional activity of peripheral blood leukocytes from electron microscopic data was estimated in 200 infants. It was shown that the use of antibiotics in combination with immunostimulants such as leukocyte mass, lysozyme and prodigiozan in complex therapy of salmonellosis in infants had a favourable effect on both the time course of the clinical signs and the functional state of the neutrophil leukocytes. The duration of the treatment decreased by 6.14 +/- 0.34 days and repeated isolation of the pathogen from the host appeared to be less frequent.

[Use of the stimulants of nonspecific resistance in the complex treatment of infectious complications in patients with chronic myeloid leukemia]. / Primenenie stimuliatorov nespetsificheskoi rezistentnosti organizma v kompleksnom lechenii infektsionnykh oslozhnenii u bol'nykh khronicheskim mieloleikozom.

Effectiveness of three methods of infectious complication therapy in chronic myeloleukemia (CML) patients was studied. Group I patients (n = 20) received antibiotics, group II patients (n = 9) were given antibiotics with gamma-globulin, in group III antibiotics combined with individually selected immunomodulators were used. The highest effect was recorded in CML patients who received antibiotics combined with the immunomodulators that has led to normalization of cellular and humoral factors of nonspecific body resistance.

[Antibiotic therapy of acute dysentery in children with immunologic deficiency conditions]. / Antibiotikoterapiia ostroi dizenterii pri immunodefitsitnom sostoianii organizma u detei.

One hundred children with acute Sonnei and flexneri dysentery were followed up with respect to the infection process and main immunity indices. In 32 children the immunity indices were physiological (group 1) and in 68 children secondary immune deficiency was observed (group 2). The children were treated with aminoglycoside antibiotics and prodigiozan and it was stated that the time of recovery in the children with immune deficiency was longer by 5.2 days as compared to that in the children without immune deficiency. In the children with immune deficiency the combined use of one of the aminoglycosides, prodigiozan and lysozyme, led to a reduction of the host immunological reactivity and recovery within the same periods as those recorded for children with the physiological immunity status. It is recommended to use the antibiotic combination with prodigiozan and lysozyme in the treatment of all the forms of dysentery in children with secondary immune deficiency.

[Evaluation of liposomal forms of rifampicin and prodigiozan in the treatment of experimental chronic tonsillitis]. / Otsenka liposomal'nykh form rifampitsina i prodigiozana pri lechenii éksperimental'nogo khronicheskogo tonzillita.

Therapeutic effect of liposomal dosages of rifampicin and prodigiozan was studied on rabbits with simulated chronic tonsillitis in comparison to that of commercial ones of the drugs. The treatment schemes included daily intra-tonsillar++ injections of the dosage forms for 5 days. A high efficacy of their liposomal dosage forms in treatment of experimental chronic tonsillitis was confirmed microbiologically and immunologically. Approval of the liposomal dosage forms used in the therapy of patients with chronic tonsillitis requires clinical trials.

[The effect of stimulants of immunity on anti-infective resistance and on the activity of the liver monooxygenase system]. / Vliianie nekotorykh stimuliatorov immuniteta na antiinfektsionnuiu rezistentnost' i aktivnost' monooksigenaznoi sistemy pecheni.

The effect of some immunostimulants (bacterial lipopolysaccharide prodigiosan, active thymic peptide T-activin, synthetic compound levamisole) on the anti-infection resistance and metabolic function of the liver (hexobarbital sleeping-time) was studied on noninbred male mice. It was found that when administered in doses and under schedules that protected mice against lethal infection (Pseudomonas pyocyanea, i.p.) prodigiosan and levamisole inhibited metabolism of hexobarbital. T-activin was inactive in both tests. The possible mechanism of correlation is discussed.

[Radiation pathomorphosis of experimental squamous cell cancer during mono- and polyradiomodifications]. / Luchevoi patomorfoz ploskokletochnogo raka v éksperimente pri mono- i poliradiomodifikatsii.

The authors presented experimental data on the assessment of radiation pathomorphosis of squamous cell carcinoma (RShM-2) in mice after single total irradiation at a dose of --Gy using radiomodifiers in various combinations. Blood flow inhibition used independently was shown to be and important factor in the implementation of the radiation antitumor effect. Good results were obtained in the combined use of blood flow inhibition and short-term induced hyperglycemia, the best results were achieved with the combined use of radiomodifiers during blood flow inhibition.

[Clinico-pathogenetic substantiation of the immunocorrective treatment of pyelonephritis in infants]. / Kliniko-patogeneticheskoe obosnovanie immunokorrigiruiushchei terapii pielonefrita u detei rannego vozrasta.

The results of the treatment of 47 babies treated with the immunocorrecting drugs (t-activin, levamisole, sodium nucleinate, prodigiozan, lysozyme) together with antimicrobial remedies are described. The babies were selected from 120 patients suffering from pyelonephritis. Indications for use of the immunomodulators included the deficiency of the T component of immunity, of phagocytosis and, more rarely, of B lymphocytes, an unfavourable premorbed condition, severe lingering disease course as well as low efficacy of antibacterial therapy. Two control groups consisted of 120 patients who were not given the immunocorrecting remedies and 30 normal children of the first year of life. The immunostimulation therapy minimized the duration of the active phase of pyelonephritis, decreasing the rate of relapses and the probability that the disease may progress to a chronic course. The positive influence of the above drugs on the clinical picture of pyelonephritis enabled the duration of antibacterial therapy, the dosage and the frequency of antibiotic use to be reduced. The favourable outcome of pyelonephritis was followed by gradual normalization of the immunological parameters.

[Value of determining the spectrum of blood serum fatty acids in evaluating increasing the effectiveness of antibiotic therapy of dysentery in children with prodigiozan and ephedrine]. / Znachenie opredeleniia spektra zhirnykh kislot syvorotki krovi pri otsenke povysheniia èffektivnosti antibiotikoterapii prodigiozanom i efedrinom pri disenterii u detei.

One hundred and ninety one children with acute Sonne and Flexner dysentery were observed with respect to the disease process, immunity indices and blood serum fatty acid spectrum. 104 children were treated with monomycin alone and 87 children were treated with the antibiotic in combination with prodigiozan and ephedrine as immunostimulators. It was shown that the recovery terms in the patients treated with the use of the immunostimulators decreased as compared to the patients treated with the antibiotic alone. The fatty acid spectrum in the children treated with the use of the immunostimulators differed from that in the children treated without them by low levels of fatty acids of the C12:0 to C18:1 composition.

[Effect of combinations of immunomodulators on phagocytosis]. / Vliianie kombinatii immunomoduliatorov na fagotsitoz.

The effect of levamisole, prodigiozan and lithium carbonate combinations on antimicrobial activity of blood neutrophils and peritoneal macrophages was studied on mice. The combinations were used in single doses. An increase in stimulation of phagocytosis with respect to staphylococci was observed after the use of prodigiozan in combination with lithium carbonate. Levamisole and lithium carbonate were antagonistic with respect to macrophagal phagocytosis. No advantage of the combined use of prodigiozan and levamisole to their use alone was shown.

Prodigiozán como inductor de interferón para la prevención de infecciones virales respiratorias agudas en los niños / Prodigiozan as inducer of IFN for the prevention of acute respiratory viral infections in children

En el otoño y el invierno de 1981-1982 y de 1982-1983, se probó el Prodigiozán en las instituciones prescolares de Tallín, como medio protector contra las infecciones virales respiratorias agudas (IVRA). Se utilizó durante el aumento estacional y epidémico de la morbilidad por IVRA e influenza en niños de 3 y 6 años de edad. El Prodigiozán se administró por vía nasal, en dosis de 25 ó 50 mg por niño, una vez por semana, durante un período de tres semanas. Se observó que su aplicación induce la formación de IFN endógeno y que la concentración en sangre fluctúa de 8 a 64 UI50, durante las primeras 72 horas. Después de la tercera aplicación pudo apreciarse una disminución estadísticamente importante de lo títulos de IFN. En las 4ta y 5ta semanas no se encontró en la sangre, y este hecho evidencia la formación de tolerancia. Se muestra una disminución estadísticamente significativa de la morbilidad por IVRA de 2.5 a 2.9 veces durante el período de administración del medicamento. Después de completar la administración del Prodigiozán, no se observó una importante reducción de morbilidad por IVRA ni influenza

Prodigiozán como inductor de interferón para la prevención de infecciones virales respiratorias agudas en los niños / Prodigiozan as inducer of IFN for the prevention of acute respiratory viral infections in children

En el otoño y el invierno de 1981-1982 y de 1982-1983, se probó el Prodigiozán en las instituciones prescolares de Tallín, como medio protector contra las infecciones virales respiratorias agudas (IVRA). Se utilizó durante el aumento estacional y epidémico de la morbilidad por IVRA e influenza en niños de 3 y 6 años de edad. El Prodigiozán se administró por vía nasal, en dosis de 25 ó 50 mg por niño, una vez por semana, durante un período de tres semanas. Se observó que su aplicación induce la formación de IFN endógeno y que la concentración en sangre fluctúa de 8 a 64 UI50, durante las primeras 72 horas. Después de la tercera aplicación pudo apreciarse una disminución estadísticamente importante de lo títulos de IFN. En las 4ta y 5ta semanas no se encontró en la sangre, y este hecho evidencia la formación de tolerancia. Se muestra una disminución estadísticamente significativa de la morbilidad por IVRA de 2.5 a 2.9 veces durante el período de administración del medicamento. Después de completar la administración del Prodigiozán, no se observó una importante reducción de morbilidad por IVRA ni influenza